v3.26.1
Liquidity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
May 12, 2026
Mar. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from the exercise of common stock warrants     $ 44,084 $ 503  
Exercised (in shares)     28,200,000    
Weighted average exercise price (in dollars per share)   $ 1.56 $ 1.56    
Upfront fee and milestone payments     $ 10,500    
Potential milestone payments to be received     191,500    
Cash and cash equivalents   $ 107,097 107,097   $ 71,793
Restricted cash and cash equivalents   100 100   100
Accumulated deficit   283,395 283,395   $ 274,988
Net loss     8,407 5,813  
Net cash used in operating activities     $ 8,846 $ 9,070  
At-The-Market Equity Offering Program (2026 ATM)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net proceeds of common stock   $ 150,000      
Number of shares of common stock sold (in shares)   0      
Subsequent Event          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from the exercise of common stock warrants $ 7,500        
Exercised (in shares) 4,700,000        
Weighted average exercise price (in dollars per share) $ 1.60        
Proceeds from warrant exercises $ 7,500